Navigation Links
Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings

TSX: BMR

TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as an important molecular target for the development of new treatments for glioblastoma multiforme (GBM).

The researchers identified that the loss of NOTCH2 gene positively predicts survival in subgroups of human glial brain tumors (http://www.plosone.org/doi/pone.0000576) and these markers are highly predictive of survival in subgroups of GBM patients. Ongoing work at the Laboratory of Molecular Neuro-Oncology, Department of Research, University Hospital, Basel, Switzerland has reported that NOTCH2 upregulates tenascin and that high tenascin-C expression reduces the prognosis of disease-free survival in patients with some cancers (Cancer Lett.2006 Dec 8;244(2):143-63. Epub 2006).

Tenascin-C is an extracellular matrix protein that is highly expressed in the microenvironment of glioblastoma and is the molecular target for Bradmer's lead clinical candidate, Neuradiab.

"This new research confirms that Neuradiab is targeting a key marker in the progression of GBM that is also expressed in virtually all GBM cases. This is important because selectively targeting a widely expressed marker is critical to developing a broadly effective GBM therapy," said Dr. Alan Ezrin, Chief Operating Officer of Bradmer. "The results of this new article add to a growing base of recent scientific research which supports the rationale for targeting tenascin-C with a local mechanism of action in the GBM setting. This ongoing research complements the profile and mechanism of action of Neuradiab. In a series of Phase I and Phase II trials, Neuradiab has demonst
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
3. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
10. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
(Date:9/23/2014)...   LabStyle Innovations Corp . (OTCQB: DRIO), ... announced that it has closed a $4.2 million ... stock and warrants.  No placement agent was used ... expects to secure net proceeds of approximately $4.1 ... intends to use the net proceeds from the ...
(Date:9/23/2014)... --  MedNet Solutions , a global life sciences technology company ... that it will once again be a Silver Sponsor of ... be held this year from September 28 to October 1 ... in conjunction with representatives from many of its ... attendance, will be providing demonstrations of iMedNet EDC ...
(Date:9/23/2014)... and DUBLIN , Sept. 23, ... or the "Company"), a biotechnology company pioneering the ... diseases in emerging nations, today announced that the ... stock for DTC,s Deposit and Withdrawal at Custodian ... Service ("FAST") transfer agent as the distribution point. ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5MedNet Solutions - Proud To Sponsor The SCDM 2014 Annual Conference 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... (Nasdaq: ONXX ) today announced that it will ... Conference on Wednesday, March 9, 2011 at 11:00 a.m. Eastern ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... WASHINGTON, March 2, 2011 A new ad ... S.B. 2445 would raise taxes on prescription drug benefits ... to reduce health care costs for Mississippi families and ... S.B. 2445 would also put the State ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates 'Conflict of Interest' 2
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. ... low birth weights, breast milk is more likely than a ... as cytomegalovirus (CMV), a new study finds. The researchers ... all of whom weighed 3.3 pounds or less and many ... infection, to see whether breast milk or transfusions carried the ...
(Date:9/23/2014)... -- Both drinking and getting drunk at an early ... high school students, a new study suggests. The ... who drink, could help expand alcohol-prevention efforts aimed at ... them from becoming binge drinkers, the researchers suggested. , ... use and progression to first heavy use as risk ...
(Date:9/23/2014)... What information do patients need to ... (NQF) released a report ( http://bit.ly/1DwekE9 ), consumer ... ( http://bit.ly/1tX3lzA ) resulting from an in-depth look ... define affordability, and what information and changes are ... healthcare at the lowest possible cost. ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2
... genome of a novel strain of Clostridium botulinum , ... strain produces an unusual botulinum neurotoxin, known as type A5 ... following a case of wound botulism. Professor Mike ... Research (IFR) study Clostridium botulinum . Their expertise ...
... who comes to a health care centre does increase the ... a new study confirms. The study, led by Patricia ... St. Michael,s Hospital, represents a major reversal of thinking about ... intimate partner violence. Until now, the research and health ...
... ISRAEL, March 7, 2011 Elderly drivers are half as ... limited field of view, and compensate in part by driving ... the Negev (BGU) researchers. In the online edition ... reaction times and perception of pedestrians as hazards between experienced ...
... a year on remediation at hazardous waste sites, with ... Yet according to Rolf Halden, a researcher at Arizona ... of limited value. Under a new three-year, $1.15 ... assistant director at the Institute,s Swette Center for Environmental ...
... AstraZeneca HealthCare Foundation program, Connections for Cardiovascular HealthSM, today ... University of Michigan Health System to expand Project Healthy ... and is designed to reduce childhood obesity and its ... that it lowers total cholesterol and blood pressure in ...
... (HealthDay News) -- The sooner rehabilitation begins after knee ... research suggests. In the study, published March 7 ... compared more than 150 patients who began rehabilitation within ... control group of patients who began rehabilitation 48 to ...
Cached Medicine News:Health News:Genome sequencing used to assess a novel form of Clostridium botulinum 2Health News:Universal screening programs can uncover abuse, study finds 2Health News:Elderly see pedestrians half as often as younger drivers, according to Ben-Gurion U. researchers 2Health News:Monitoring waste in groundwater (without all the waste) 2
Human based material available in two levels for thecontrol of percision for up to 10 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Therapeutic Drug Calibrator Series...
Medicine Products: